openPR Logo
Press release

Heparin Market is Expected to Reach at Value US$ 16,385.7 Mn and Volume 36.7 Million Megas Globally By 2025

11-17-2017 08:10 AM CET | Health & Medicine

Press release from: Transparency Market Research

Heparin Market is Expected to Reach at Value US$ 16,385.7 Mn

According to the report, the global heparin market was valued at US$ 9,549.0 Mn in 2016 and is projected to expand at a CAGR of 6.2% during forecast period from 2017 to 2025 to reach US$ 16,385.7 Mn in 2025. The global heparin market volume was accounted for 28.8 million megas in 2016 and is expected to grow at a CAGR of 2.7% during the forecast period from 2017 to 2025 to reach at 36.7 million megas by 2025.

Heparin is administered intravenously or subcutaneously which functions by inhibiting the effects of antithrombin and Factor Xa. Patients suffering from stroke and unstable angina are usually recommended heparin therapy owing to rapid onset of anticoagulation activity. Additionally, heparin is also advised to patients suffering from stroke or transient ischemic attack. Heparin is also among the most widely used anticoagulant after warfarin during surgical procures and treatment of coagulation disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Read Report - https://www.transparencymarketresearch.com/heparin-market.html

The report on global heparin market consist the study on value and volume of heparin by product, source, and formulation. On the basis of products heparin market has been studied for unfractionated heparin, low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). On the basis of source the global heparin market is categorized into bovine and porcine source. On the basis of formulation the global heparin market is segmented in to oral and parenteral formulations.

Unfractionated heparin is one of the most primitive forms of heparin commonly used during dialysis and in heart lung machines as a measure to prevent blood clots. Unfractionated heparin has variable anticoagulant effect with limited bioavailability which is a major drawback affecting sales and acceptance with heparin base products. However, heparin overdose associated with unfractionated heparin can be easily reversed with protamine sulfate as compared to LMWHs and ULMWHs. Due to its large molecular size and anionic structure, unfractionated heparin is not absorbed reliably in the gastrointestinal tract when administrated orally. Heparin induced thrombocytopenia and hemorrhage are some of the major adverse effects of unfractionated heparin therapy.

Inquire for a Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=803

LMWH products have smaller and more uniform molecular weights than unfractionated heparin leading to greater affinity for Factor Xa than Factor IIa. Compared to unfractionated heparin, LMWHs have enhanced safety and efficacy. LMWHs accounted for the largest market share in 2014 owing to its broad applications and consumption. LMWHs are produced by depolymerization of unfractionated heparin. Each LMWH product has a specific molecular weight distribution which determines its anticoagulant activity and duration of action. Majority of the branded LMWH drugs in the global heparin market have gone off patent, thereby offering market access to generic manufacturers. However, manufacturing of LMWH entails harsh enzymatic and/or chemical processes that lead to a few structural changes in the final product. Thus, specific guidelines laid by the regulatory authorities are to be met for final approval of the generic heparin product. Additionally, regulatory agencies such as the U.S. FDA and World Health Organization (WHO) consider each LMWH as a distinct drug requiring clinical validation data for specific indications. In Europe and the U.S., several pharmaceutical giants have applied for the marketing rights of Enoxaparin (Sanofi-Aventis U.S. LLC) and the Dalteparin (Pfizer, Inc. / Eisai Co., Ltd) brands.

Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=803

Ultra-Low Molecular Weight Heparins (ULMWHs) have molecular weight lower than 4000 Da, and are available with enhanced anti-factor Xa activity compared to LMWHs. Over the past decade, ULMWHs such as Arixtra (Aspen) have been widely used across the globe. However, chemical-based methods for processing and synthesizing ULMWHs have increased the overall cost of product becoming a major drawback in this product segment. Additionally, low yield and the possibility of contamination during manufacturing also adversely affects the overall demand for ULMWHs. As a measure to overcome restraints associated with ULMWHs, researchers at University of North Carolina have developed novel method to produce two new ULMW heparins through series of bio-enzymatic process. Such advancements will positively affect the market growth and demand in forthcoming years. Moreover, advent of generic versions of Arixtra are expected to propel the market growth with possible price containment.

Major players in the global heparin market includes Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, and Syntex S.A. among others.

Purchase this Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=803

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Heparin Market is Expected to Reach at Value US$ 16,385.7 Mn and Volume 36.7 Million Megas Globally By 2025 here

News-ID: 821193 • Views: 155

More Releases from Transparency Market Research

Monochloroacetic Acid Market Demand, Prominent Players and Growth By 2027
Albany, NY - The global monochloroacetic acid market was valued at US$ 815.74 Mn in 2018 and is anticipated to expand at a CAGR of approximately 4.0% during the forecast period, according to a new report titled ‘Monochloroacetic Acid Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’ published by Transparency Market Research (TMR) The report infers to the usage of monochloroacetic acid for oil drilling activities. Asia Pacific is
Polyethylene Furanoate (PEF) Market Poised to Expand at a Robust Pace Over 2019- …
Polyethylene Furanoate (PEF) Market: Bio-based Substitute for Polyethylene Terephthalate • Polyethylene Furanoate (PEF) is commonly called as the next generation polyester. It has the capability to replace polyethylene terephthalate (PET). PET is a durable polymer derived from conventional synthetic resources. • PEF is manufactured by polymerization of furandicarboxylic acid (FDCA) in the presence of ethylene glycol. FDCA is produced by using raw materials such as starch, sugar, and cellulose. These materials are extensively produced
Miso Market Estimated to Experience a Hike in Growth by 2020-2030
Global Miso Market: Overview The demand within the global miso market is set to touch unprecedented levels in the times to come by. The growing popularity of cultural foods has given an impetus to the expansion of the miso market. Besides, the taste imparted by miso to several traditional dishes has created humongous opportunities for growth across the global miso market. The next decade could witness the perfecting of several recipes
Walnut Market Set to Witness an Uptick during 2020 to 2030
Global Walnut Market: Snapshot Recent lifestyle shifts have led people to look for options that are packed with essential nutrients. And, the search has led them to superfoods. And, nuts are particularly known to be super-effective in this domain. Considering, that just a handful is sufficient in to cover a significant portion of daily calorific intake and a respectable portion of minerals and vitamins. And, walnut are no different. Rich in

All 5 Releases


More Releases for LMWH

Crude Heparin Market Size to Surge Vigorously during the Forecast Period
Crude Heparin: One of the Most Widely Used Natural Products in Medicine Heparin is a widely used, strongly charged polysaccharide anticoagulant agent. It is used as a drug and incorporated in devices. Heparin is used to treat and prevent blood clots caused by certain medical conditions or medical procedures. It is also used before surgery to reduce the risk of blood clots. Crude heparin is obtained primarily from bovine and porcine sources. Moreover,
Injectable Anticoagulants Market: Huge Growth Opportunities and Challenges to Wa …
Injectable Anticoagulants Market report includes (5 Year Forecast 2019-2024) an extensive analysis of competition by topmost prime manufacturers (Sanofi, Genentech (Roche), Boehringer Ingelheim, Pfizer, The Medicines Company , Aspen, Otsuka) which providing various attributes such as Company Profiles, Product Picture and Specification, Business Strategies, Recent Developments, Capacity, Production, Price, Cost, Revenue and contact information. The Injectable Anticoagulants market report provides a basic summary of the business together with definitions, classifications, applications and business chain structure. The
Global Heparin Market: Segment Snapshot and Table of Content (2017-2027)
TMR has envisaged the global heparin market to earn an around US$16.3 bn by the end of 2025 while rising at a CAGR of 6.2% during the forecast time frame 2017-2025. In 2017, the market earned an approximately US$10.1 bn. With respect to segmentation by product, low molecular weight heparin (LMWH) could account for a colossal share in the market by the completion of the forecast period. Regionally, North America
United States Injectable Anticoagulants Market by Manufacturers, States, Type an …
ReportsWorldwide has announced the addition of a new report title United States Injectable Anticoagulants Market by Manufacturers, States, Type and Application, Forecast to 2022 to its growing collection of premium market research reports. The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin], enoxaparin [Lovenox]) and factor Xa inhibitors (fondaparinux [Arixtra]). In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism. Scope of
Global Anticoagulants Market Size, Shares, Segments, Trends & Forecasts (2016-20 …
The report entitled Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020) provides an analysis of the global anticoagulants market with detailed description of market size & growth and market share by products. The report also provides a detailed analysis of anticoagulants available in the market. Details of Lovenox, Arixtra, Fraxiparine (injectable anticoagulants), Xarelto, Pradaxa and Eliquis (NOACs) has provided in terms of their worldwide sales. The report provides detailed regional analysis of
New study on Global Anticoagulants Market Size, Growing Rapidly, Trends & Foreca …
The report entitled Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020) provides an analysis of the global anticoagulants market with detailed description of market size & growth and market share by products. The report also provides a detailed analysis of anticoagulants available in the market. Details of Lovenox, Arixtra, Fraxiparine (injectable anticoagulants), Xarelto, Pradaxa and Eliquis (NOACs) has provided in terms of their worldwide sales. The report provides detailed regional analysis of